# Exozymes Inc.: overview EXOZ · Nasdaq · CIK 2010788 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/exoz.md) · [Financials](/companies/exoz/financials.md) · [Filings](/companies/exoz/filings.md) · [Insiders](/companies/exoz/insiders.md) Latest reported revenue: [−$700](/filings/0001641172-25-001744.md) for period not labelled, three months to 2023-12-31, from the 10-K filed Mar 31, 2025 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001641172-25-001744). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.27)](/filings/0001493152-25-022289.md) | not reported | [(0.22)](/filings/0001493152-26-023035.md) | [(0.28)](/filings/0001493152-26-037725.md) | [(0.27)](/filings/0001493152-25-022289.md) | not reported | [(0.28)](/filings/0001493152-26-023035.md) | [(0.33)](/filings/0001493152-26-037725.md) | | Free cash flow | $k | [(542) d](/filings/0001493152-25-022289.md) | [(5,918) d](/filings/0001493152-26-013563.md) | [(1,165)](/filings/0001493152-26-023035.md) | [(1,589) d](/filings/0001493152-26-037725.md) | [(1,870) d](/filings/0001493152-25-022289.md) | [(2,049) d](/filings/0001493152-26-013563.md) | [(1,582)](/filings/0001493152-26-023035.md) | [(1,640) d](/filings/0001493152-26-037725.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | | Revenue | $k | [70.1](/filings/0001641172-25-001744.md) | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | | Operating margin | % | [(2563.5%)](/filings/0001641172-25-001744.md) | not reported | not reported | | Net margin | % | [(2909.1%)](/filings/0001641172-25-001744.md) | not reported | not reported | | Diluted EPS | $ per share | [(0.33)](/filings/0001641172-25-001744.md) | [(0.89)](/filings/0001493152-26-013563.md) | [(1.09)](/filings/0001493152-26-013563.md) | | Free cash flow | $k | [(1,470)](/filings/0001641172-25-001744.md) | [(8,902)](/filings/0001493152-26-013563.md) | [(6,672)](/filings/0001493152-26-013563.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/exoz/insiders.md) | Date | Insider | Role | Transaction | Shares | Reported price | Value | Filing | | --- | --- | --- | --- | ---: | ---: | ---: | --- | | 2026-10-12 | [Perriman Damien Alan](/insiders/2096714.md) | Chief Commercial Officer, Officer | Sale (S) | 3,729 | $5.2096 | $19.4k | [Form 4](/filings/0001493152-26-048493.md) | ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $463.5k | 54,985 | | Added +32,795 | | [Davidson Kahn Capital Management, LLC](/funds/2055535.md) | 2026-06-30 | $210.8k | 25,000 | | New +25,000 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $197.3k | 23,406 | | Added +1,515 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $81.0k | 9,610 | | Added +2,813 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $79.5k | 9,426 | | Unchanged | | [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $10.5k | 1,250 | | Unchanged | | [Tower Research Capital LLC (TRC)](/funds/1533421.md) | 2026-06-30 | $2.9k | 349 | | Reduced −968 | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $1.7k | 203 | | Added +179 | | [BARCLAYS PLC](/funds/312069.md) | 2026-06-30 | $632 | 75 | | New +75 | ## Recent filings [All 126 filings](/companies/exoz/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-09 | 12:10 ET | [8-K](/filings/0001493152-26-046456.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-046456 | | 2026-09-28 | 17:25 ET | [DEF 14A](/filings/0001140361-26-037859.md) | Proxy statement, period 2026-11-13 | 0001140361-26-037859 | | 2026-09-18 | 13:24 ET | [8-K](/filings/0001493152-26-043288.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-043288 | | 2026-08-13 | 15:50 ET | [10-Q](/filings/0001493152-26-037725.md) | Quarterly report, period 2026-06-30 | 0001493152-26-037725 | | 2026-07-01 | 16:30 ET | [8-K](/filings/0001493152-26-031560.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001493152-26-031560 | | 2026-06-26 | 19:36 ET | [8-K](/filings/0001493152-26-030205.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-030205 | | 2026-06-17 | 17:11 ET | [8-K](/filings/0001493152-26-029119.md) | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-029119 | | 2026-06-08 | 14:19 ET | [8-K](/filings/0001493152-26-027688.md) | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-027688 | | 2026-05-14 | 15:50 ET | [10-Q](/filings/0001493152-26-023035.md) | Quarterly report, period 2026-03-31 | 0001493152-26-023035 | | 2026-05-07 | 06:08 ET | [8-K](/filings/0001493152-26-021589.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-021589 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001493152-26-013563.md), filed Mar 30, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 2010788 - Tickers: EXOZ - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: NV - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 26, 2026, 15:02 ET. No prices; not investment advice.